Geron Corporation (GERN) - Total Assets
Based on the latest financial reports, Geron Corporation (GERN) holds total assets worth $534.12 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Geron Corporation cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Geron Corporation - Total Assets Trend (1996–2025)
This chart illustrates how Geron Corporation's total assets have evolved over time, based on quarterly financial data. Explore how much of Geron Corporation's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Geron Corporation - Asset Composition Analysis
Current Asset Composition (December 2025)
Geron Corporation's total assets of $534.12 Million consist of 91.2% current assets and 8.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.9% |
| Accounts Receivable | $39.23 Million | 6.9% |
| Inventory | $116.64 Million | 20.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2025)
This chart illustrates how Geron Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GERN company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Geron Corporation's current assets represent 91.2% of total assets in 2025, an increase from 86.8% in 1996.
- Cash Position: Cash and equivalents constituted 13.9% of total assets in 2025, down from 43.1% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is inventory at 20.4% of total assets.
Geron Corporation Competitors by Total Assets
Key competitors of Geron Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Geron Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.78 | 7.87 | 5.45 |
| Quick Ratio | 4.96 | 6.97 | 5.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $424.96 Million | $432.74 Million | $164.75 Million |
Geron Corporation - Advanced Valuation Insights
This section examines the relationship between Geron Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.28 |
| Latest Market Cap to Assets Ratio | 1.27 |
| Asset Growth Rate (YoY) | -3.9% |
| Total Assets | $570.54 Million |
| Market Capitalization | $724.92 Million USD |
Valuation Analysis
Above Book Valuation: The market values Geron Corporation's assets above their book value (1.27x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Geron Corporation's assets decreased by 3.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Geron Corporation (1996–2025)
The table below shows the annual total assets of Geron Corporation from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $570.54 Million | -3.91% |
| 2024-12-31 | $593.78 Million | +50.68% |
| 2023-12-31 | $394.08 Million | +106.78% |
| 2022-12-31 | $190.57 Million | -15.69% |
| 2021-12-31 | $226.03 Million | -16.51% |
| 2020-12-31 | $270.73 Million | +63.57% |
| 2019-12-31 | $165.52 Million | -10.67% |
| 2018-12-31 | $185.28 Million | +67.96% |
| 2017-12-31 | $110.31 Million | -15.31% |
| 2016-12-31 | $130.25 Million | -12.44% |
| 2015-12-31 | $148.76 Million | -13.77% |
| 2014-12-31 | $172.51 Million | +156.16% |
| 2013-12-31 | $67.34 Million | -32.52% |
| 2012-12-31 | $99.80 Million | -37.64% |
| 2011-12-31 | $160.05 Million | -31.48% |
| 2010-12-31 | $233.58 Million | +29.49% |
| 2009-12-31 | $180.38 Million | +2.36% |
| 2008-12-31 | $176.22 Million | -19.50% |
| 2007-12-31 | $218.90 Million | -0.86% |
| 2006-12-31 | $220.80 Million | +9.72% |
| 2005-12-31 | $201.24 Million | +52.60% |
| 2004-12-31 | $131.87 Million | +11.65% |
| 2003-12-31 | $118.11 Million | +94.69% |
| 2002-12-31 | $60.67 Million | -36.95% |
| 2001-12-31 | $96.23 Million | -15.61% |
| 2000-12-31 | $114.03 Million | +79.01% |
| 1999-12-31 | $63.70 Million | +43.15% |
| 1998-12-31 | $44.50 Million | +70.50% |
| 1997-12-31 | $26.10 Million | -9.38% |
| 1996-12-31 | $28.80 Million | -- |
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lowe… Read more